Pacific Edge revenues up, cash costs down on reorganisation

The Market Herald05-21

Cancer diagnostic pharmaceutical company Pacific Edge Ltd (ASX:PEB) has reported a drop of 24 percent in cash costs in the second half of the Financial Year, based on a reorganisation of the company, ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2437243413?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-05-21 08:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2437243413","market":"us","top_or_hot":-1,"title":"Pacific Edge revenues up, cash costs down on reorganisation","media":"The Market Herald","content":"<div>\n<p>Cancer diagnostic pharmaceutical company Pacific Edge Ltd (ASX:PEB) has reported a drop of 24 percent in cash costs in the second half of the Financial Year, based on a reorganisation of the company, ...</p>\n\n<a href=\"https://themarketonline.com.au/pacific-edge-revenues-up-cash-costs-down-on-reorganisation-2024-05-21/\">Source Link</a>\n\n</div>\n","source":"markerherald_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pacific Edge revenues up, cash costs down on reorganisation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPacific Edge revenues up, cash costs down on reorganisation\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-05-21 08:06 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://themarketonline.com.au/pacific-edge-revenues-up-cash-costs-down-on-reorganisation-2024-05-21/><strong>The Market Herald</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Cancer diagnostic pharmaceutical company Pacific Edge Ltd (ASX:PEB) has reported a drop of 24 percent in cash costs in the second half of the Financial Year, based on a reorganisation of the company, ...</p>\n\n<a href=\"https://themarketonline.com.au/pacific-edge-revenues-up-cash-costs-down-on-reorganisation-2024-05-21/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7067","symbol_name":"生物科技","start_time":0,"source_url":"https://themarketonline.com.au/pacific-edge-revenues-up-cash-costs-down-on-reorganisation-2024-05-21/","article_id":"2437243413","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2437243413","pubTimestamp":1716249960,"sourceInfo":{"source_id":"markerherald_stock","name":"The Market Herald"},"weMediaInfo":null,"summary":"Cancer diagnostic pharmaceutical company Pacific Edge Ltd  has reported a drop of 24 percent in cash costs in the second half of the Financial Year, based on a reorganisation of the company, in addition to revenue growth throughout the year ahead of its chairman Chris Gallaher stepping down.Pacific Edge’s ‘cash burn’ fell to $11.9 million in the second half of Financial Year 2024, down 24 percent compared to the first half of the year. This was also influenced by caution regarding capital spending, with a focus on the company’s long-term goals.However, the company also experienced a fall in cash and cash equivalents, from $62.2 million in September 2023 to $50.3 million.At the same time, revenue grew 12 percent in the same Financial Year, boosted by increased collections and the higher volumes – by 2 percent – of its patented bladder cancer diagnostic tests Cxbladder available on the US market.“The Board is working through the Nominations Committee to identify my successorwho will lead","collect":0,"end_time":0,"defaultTopTitle":"themarketonline.com.au","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7067":"生物科技","PEB.AU":"PACIFIC EDGE LTD"},"translate_title":"Pacific Edge收入上升，重组后现金成本下降","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PEB.AU":1},"content_text":"Cancer diagnostic pharmaceutical company Pacific Edge Ltd (ASX:PEB) has reported a drop of 24 percent in cash costs in the second half of the Financial Year, based on a reorganisation of the company, in addition to revenue growth throughout the year ahead of its chairman Chris Gallaher stepping down. \nPacific Edge’s ‘cash burn’ fell to $11.9 million in the second half of Financial Year 2024, down 24 percent compared to the first half of the year. This was also influenced by caution regarding capital spending, with a focus on the company’s long-term goals.\nHowever, the company also experienced a fall in cash and cash equivalents, from $62.2 million in September 2023 to $50.3 million.\nAt the same time, revenue grew 12 percent in the same Financial Year, boosted by increased collections and the higher volumes – by 2 percent – of its patented bladder cancer diagnostic tests Cxbladder available on the US market.\nTotal revenue was sitting at $29.3 million based on this rise, while operating revenue for the year had grown 22 percent, to $23.9 million.\nThe number of Cxbladder tests put through laboratories rose 3 percent to 32,633 tests, while commercial tests increased by 2 percent to 27,347, although there was some reduction in the second half of the year, based on a reduction in the company’s sales team.\nPacific Edge also saw its earnings from tests increase by 18 percent (per test, according to average US sales price), from US$519 in the second half of 2023 to US$613 in the second half of 2024. \nThis was based on increased volumes from major private payer Kaiser Permanente, and improvements in cash collection.\nChairman Chris Gallaher said he was pleased with how Pacific Edge was tracking regarding its developments for the US market.\n“The Board is pleased with the progress Peter and his team have made as we work towards gaining certainty on Medicare coverage of our tests,” he said. \n“They have acted swiftly regarding the need to preserve capital through uncertainty and retained their focus on the strategic imperatives in clinical evidence generation that will underpin our future success and prepare the company for all outcomes. \n“As announced in March, I will be stepping down as the Chairman of Pacific Edge at the endof the year. \n“The Board is working through the Nominations Committee to identify my successorwho will lead the Company into the next phase of its development.”","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2437243413"}